Aptamer Oligonucleotides for Microvesicle Antigen Detection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current diagnostic and therapeutic approaches for cancer and other diseases involving microvesicles lack specificity and efficiency, particularly in detecting biomarkers and targeting microvesicle surface antigens effectively.
Innovation Solution
Development of aptamers that bind specifically to microvesicle surface antigens, allowing for diagnostic and therapeutic applications through oligonucleotide compositions and methods that enable precise detection and modulation of microvesicle-related biomarkers.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If traditional antibodies are used for diagnostic and therapeutic applications, then binding capability is achieved, but toxicity and immunogenicity increase
Solution Approach 1:
The patent employs aptamers (short nucleic acid sequences) instead of traditional antibodies. These aptamers are chemically synthesized, have short half-lives in the body, and do not trigger immunogenic responses. The short-living nature of aptamers eliminates the need for complex purification and reduces toxicity, while maintaining binding capability through high-affinity interactions with target microvesicle surface antigens.
Solution Approach 2:
The patent changes the fundamental parameter of the binding molecule from protein (antibody) to nucleic acid (aptamer). This parameter change transforms the molecular properties: aptamers are chemically stable, non-immunogenic, and can be chemically modified for enhanced binding affinity and pharmacokinetic properties, while avoiding the toxicity and immunogenicity inherent in protein-based therapies.
2Reliability
If monoclonal antibodies are used for cancer therapy, then therapeutic effect is achieved, but administration complexity and cost increase
Solution Approach 1:
The patent uses chemically synthesized aptamers that can be produced through straightforward chemical processes rather than complex biological purification. The synthesis process is scalable and cost-effective, producing pure aptamer molecules that require no animal-derived materials or complex formulation procedures, thereby reducing administration complexity and cost while maintaining therapeutic effect.
Solution Approach 2:
The patent replaces the biological production and purification system required for monoclonal antibodies with a chemical synthesis system. Aptamers are produced by automated oligonucleotide synthesizers, eliminating the need for cell culture, protein purification, and complex quality control procedures associated with antibody production, thus simplifying administration and reducing costs.
3Difficulty of detecting and measuring
If conventional diagnostic methods for microvesicles are used, then detection is possible, but specificity and efficiency are insufficient
Solution Approach 1:
The patent changes the detection parameter by using aptamers with specifically designed binding sequences that recognize unique microvesicle surface antigens. The aptamers can be chemically modified with fluorescent tags, radioisotopes, or other detection moieties, enabling highly specific and sensitive detection methods that surpass conventional antibody-based approaches in both specificity and efficiency.
Solution Approach 2:
The patent employs aptamer libraries containing numerous sequence variants that bind to the same target. Through in vitro selection, specific aptamer sequences are identified and used for detection. This copying approach allows for the creation of detection reagents with high specificity by selecting from multiple sequence copies that all recognize the target microvesicle surface antigen.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The aptamers provide high specificity and affinity, enabling effective diagnostic readouts and therapeutic interventions for diseases like breast cancer, with improved pharmacokinetic properties and reduced toxicity and immunogenicity compared to traditional antibodies.
Implementation Method 1
Aptamers are multi-meric nucleic acid molecules having specific binding affinity to molecules, which may be through interactions other than classic Watson-Crick base pairing
Data Source
AI summary
Methods and compositions are provided for oligonucleotides that bind target biomarkers and allow characterization of a phenotype. The target biomarkers may include microvesicle antigens, including microvesicles derived from various diseases. The characterization may comprise detection, diagnosis, prognosis, theranosis or other characterization of a disease or disorder.